Year: 2006
Type: article
Abstract: March 1, 2006, marked an historic turning point in the practice of dermatology in the United States. On this date, the iPLEDGE program—a mandatory program for managing the risk of birth defects linked to isotretinoin—replaced a voluntary predecessor initiative notable for its reliance upon a yellow sticker placed on prescriptions to indicate the patient was qualified to receive the medication.
Source: The AMA Journal of Ethic
Authors: Diane M. Thiboutot, Clay J. Cockerell
Institution: Pennsylvania State University
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W120777324